Study summary
Cadonilimab plus chemotherapy shrank most tumors as first treatment
81%of tumors shrank
What was tested
Cadonilimab, one antibody that blocks both PD-1 and CTLA-4, with paclitaxel and cisplatin as first treatment for advanced disease. No comparison group.
What they found
- Tumors shrank in 81.4% of people; 97.7% had their cancer shrink or hold steady.
- Time before the cancer grew was 7.1 months.
- Survival data were not yet mature.
What it means
High response rates are common in small first-treatment trials. A randomized trial around surgery is now running.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.